SCHEMBL8918196

SCHEMBL8918196

Clc1ccc(C(Cl)c2ccc3ncccc3c2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A2 P43354 1/20 0.50
NPC1 O15118 3/20 0.49
RAB9A P51151 2/20 0.49
POLB P06746 2/20 0.49
ALDH1A1 P00352 3/20 0.46
HTT P42858 2/20 0.46
MAPT P10636 2/20 0.46
KDM4E B2RXH2 1/20 0.46
TP53 P04637 1/20 0.46
HSP90AA1 P07900 1/20 0.46
HSP90AB1 P08238 1/20 0.46
TSHR P16473 1/20 0.46
CASP1 P29466 1/20 0.46
ATM Q13315 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HSD17B10 Q99714 1/20 0.46
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CASP6 P55212 1/20 0.42
DOT1L Q8TEK3 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10440799 0.81 NPC1 (0.57) NR4A2NPC1RAB9APOLBALDH1A1
SCHEMBL14033830 0.81 NPC1 (0.46) NPC1RAB9APOLBHTTSMN1; SMN2
SCHEMBL359841 0.79 NR4A2 (0.70) NR4A2NPC1RAB9APOLBALDH1A1
SCHEMBL18583330 0.77 NPC1 (0.49) NPC1RAB9APOLBALDH1A1HTT
Ammonia Solution, Strong SCHEMBL28220148 0.77 NR4A2 (0.68) NR4A2NPC1RAB9APOLBALDH1A1
SCHEMBL27480723 0.77 CYP19A1 (0.59) NR4A2NPC1RAB9APOLBALDH1A1
SCHEMBL6795819 0.77 PDGFRB (0.44) NPC1RAB9APOLBALDH1A1HTT
SCHEMBL10784946 0.76 NPC1 (0.78) NR4A2NPC1RAB9APOLBALDH1A1
Water SCHEMBL8916548 0.76 CYP19A1 (0.58) NR4A2NPC1RAB9APOLBALDH1A1
Water SCHEMBL8916544 0.76 CYP19A1 (0.58) NR4A2NPC1RAB9APOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5612354-A CONTROLLING CELL GROWTH AND DIFFERENTIATION, RETINOIC ACID METABOLISM JANSSEN PHARMACEUTICA N.V. (BE) 1997-03-18 US disclosed
CN-1033752-C (1H-azol-1-ylmethyl) substituted quinoline or quinolinone derivatives JANSSEN PHARMACEUTICA NV (SE) 1997-01-08 CN disclosed
US-5441954-A Treatment of disorders characterized by increased proliferation and/or abnormal differentiation of cells JANSSEN PHARMACEUTICA N. V. (BE) 1995-08-15 US disclosed
CN-1106005-A A process for preparing (1H-azol-1-ylmethyl) substituted quinoxaline derivatives JANSSEN PHARMACEUTICA NV (BE) 1995-08-02 CN disclosed
CN-1106004-A A process for preparing (1H-azol-1-ylmethyl) substituted quinazoline derivatives JANSSEN PHARMACEUTICA NV (BE) 1995-08-02 CN disclosed
EP-0371564-B1 (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives JANSSEN PHARMACEUTICA NV (BE) 1995-07-12 EP disclosed
US-5268380-A Therapy for keratinization in mammals JANSSEN PHARMACEUTICA N.V. (BE) 1993-12-07 US disclosed
US-5185346-A Antiandrogenic agents; suppress elimination of retinoids; anticarcinogenic agents HANSSEN PHARMACEUTICA (BE) 1993-02-09 US disclosed
CN-1042912-A (1H-oxazol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives JANSSEN PHARMACEUTICA NV (BE) 1990-06-13 CN disclosed
EP-0371564-A2 (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives JANSSEN PHARMACEUTICA N.V. (BE) 1990-06-06 EP disclosed